Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2026-03-05 00:00:00 ET · period of report 2026-03-05 · accession 0001875714-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-05 | 2026-03-05 | XERS | Pieper Steven | See Remarks | M - OptEx | $4.71 | +41.9K | 1.39M | +3% | +$197.3K |
| DM | 2026-03-05 | 2026-03-05 | XERS | Pieper Steven | See Remarks | M - OptEx | $0.00 | -41.9K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-05 | M | A | 14,036 | $5.93 | 1,408,940 | D | — | — | |
| 2 | Common | Common Stock | 2026-03-05 | M | A | 27,891 | $4.09 | 1,394,904 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-03-05 | M | D | 27,891 | $0.00 | 0 | D | $4.09 · — to 2030-12-10 | 27,891 Common Stock | (F1) The reporting person received the stock options on December 10, 2020 pursuant to an award under the Company's 2018 Stock Option/Stock Issuance Plan. 50% of the options vested on the first anniversary of the vesting commencement date, and the remaining 50% of options vested on the second anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-03-05 | M | D | 14,036 | $0.00 | 0 | D | $5.93 · — to 2028-01-31 | 14,036 Common Stock | (F2) The reporting person received the stock options on January 31, 2018 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date. |